Medical Doctor Program year 2020 Reported 2019–2020 Source: CMS Open Payments, 2026 publication

George Zakhia

Neurology Rochester, MN Medical Doctor

NPI 1346690906 CMS profile 2369623

200 1St St Sw, Rochester, MN 55905

Open in the dashboard

General payments

$713

11 records reported · program years 2019–2020

Research payments

$0

Paid to them · None reported · program years 2019–2020

Ownership & investment interest

$0

None reported

Through program year 2020, George Zakhia of Rochester, MN is reported in the CMS Open Payments database as having received $713 across 11 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 40th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2020 General $104 2
2019 General $609 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • George Zakhia
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to George Zakhia were reported at $0. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year George Zakhia Neurology median Middle half National median
2019 $609 $474 $118–$2,177 $163
2020 $104 $367 $82–$2,309 $114
2021 $0 $438 $104–$2,547 $132
2022 $0 $442 $103–$2,388 $149
2023 $0 $464 $119–$2,312 $160
2024 $0 $468 $119–$2,323 $164
2025 $0 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2020
  1. Biogen, Inc. $219 3 payments
  2. Novartis Pharmaceuticals Corporation $168 4 payments
  3. Amgen Inc. $121 1 payment
  4. Lilly USA, LLC $103 1 payment
  5. Neurocrine Biosciences, Inc. $103 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2020
  1. Food and Beverage $713 11 payments
Products named General payments · program years 2019–2020
  1. MAYZENT $132 3 payments
  2. AIMOVIG $121 1 payment
  3. TECFIDERA $114 1 payment
  4. INGREZZA $103 2 payments
  5. GILENYA $36 1 payment
  6. SPINRAZA $15 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 36 drugs

Part D claims

1,499

Median for Neurology: 833

Drug cost

$346,863

Median for Neurology: $202,670

Branded share of claims

33.5%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Austedo Deutetrabenazine Brand 54 $166,858
Copaxone Glatiramer Acetate Brand 13 $75,000
Lamictal Xr Lamotrigine Brand 13 $24,348
Aimovig Autoinjector Erenumab-Aooe Brand 23 $17,289
Emgality Pen Galcanezumab-Gnlm Brand 22 $14,348
Ajovy Autoinjector Fremanezumab-Vfrm Brand 14 $10,107
Carbidopa-Levodopa Carbidopa/Levodopa Brand 230 $8,499
Levetiracetam Generic 149 $5,008
Dimethyl Fumarate Generic 39 $4,454
Pyridostigmine Bromide Generic 54 $3,362

The 10 drugs with the highest cost, of 36 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$31,805

Medicare's payments for the services billed

Medicare patients

251

Average age 72

Services billed

401

138 women, 113 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Depression 41%
Chronic kidney disease 40%
Diabetes 36%
Ischemic heart disease 29%
Heart failure 27%
Atrial fibrillation 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

11 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Minnesota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2020

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record